The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...
Bayer (BAYZF) stock in focus as the company inks a licensing deal with Puhe BioPharma to develop a cancer candidate targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback